Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Last trade$8.03
Day change-$0.245 (-2.96%)
Day range$7.82 – $8.41
Volume1,968,967
Market cap$1.17B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.17B
Price / earnings
—
Price / book
8.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.94×
Profitability
Earnings per share
-$1.97
Return on assets
-53.91%
Return on equity
-197%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.36×
Current ratio
1.5×
Quick ratio
1.5×
Cash ratio
1.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$176.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CMPS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$32.98M
$23.2M
$16.42M
$16.05M
$13.21M
$12.61M
$18.74M
$16.27M
Research and development
$23.46M
$29.18M
$26.48M
$29.91M
$27.33M
$30.33M
$30.88M
$32.14M
Total operating expenses
$56.44M
$52.37M
$42.9M
$45.95M
$40.54M
$42.93M
$49.62M
$48.41M
Operating income
-$56.44M
-$52.37M
-$42.9M
-$45.95M
-$40.54M
-$42.93M
-$49.62M
-$48.41M
Interest expense
-$1.51M
-$1.48M
-$1.47M
-$1.14M
-$1.11M
-$1.15M
-$1.12M
-$1.13M
Income before taxes
-$10.94M
-$253.46M
$91.19M
-$96.61M
-$137.95M
-$38.27M
-$17.51M
-$42.31M
Income taxes
-$1.11M
$331K
-$11K
-$2.73M
-$230K
$137K
$354K
$1.02M
Net income
-$9.83M
-$253.79M
$91.2M
-$93.88M
-$137.72M
-$38.4M
-$17.86M
-$43.33M
Net income attributable to common shareholders
-$9.83M
-$253.79M
$77.64M
-$93.88M
-$137.72M
-$38.4M
-$17.86M
-$43.33M
EBITDA
-$56.44M
-$52.37M
-$42.9M
-$45.95M
-$40.52M
-$42.78M
-$49.58M
-$48.36M
Basic earnings per share
-$0.07
-$1.88
$0.71
-$0.98
-$1.44
-$0.41
-$0.20
-$0.63
Diluted earnings per share
-$0.31
-$1.88
-$0.30
-$1.08
-$1.44
-$0.41
-$0.24
-$0.63
Recent news
Company coverage with links to the original publishers.
Compass Pathways announced it will complete its New Drug Application submission for COMP360 within two weeks, positioning its synthetic psilocybin candidate for treatment-resistant depression. The company benefits from an established network of 8,500+ interventional psychiatry clinics, with 90% of surveyed psychiatrists willing to prescribe COMP360. With $444 million in cash reserves, the company is well-funded through 2028 and the planned 2027 commercial launch.
Compass Pathways is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression. With positive Phase 3 trial results and an FDA Commissioner's National Priority Voucher, the company expects to complete its FDA application by end of 2026, potentially leading to approval in early 2027. Analysts project 95% upside from current $12 share price to average target of $23.75.
Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.
An executive order fast-tracking psychedelic medicines to market has bifurcated the alternative drug sector. Psychedelic stocks like Compass Pathways and Atai Beckley surged 40% and 20% respectively due to regulatory tailwinds and short squeezes, while mature cannabis operators like Curaleaf and Innovative Industrial Properties are now valued as stable, cash-generating businesses rather than speculative plays.
Compass Pathways stock surged over 40% following a White House Executive Order aimed at accelerating approval of psychedelic drug treatments for mental health. The company's COMP360 synthetic psilocybin therapy has completed two positive phase 3 trials for treatment-resistant depression and is now on a faster regulatory track with the FDA.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.